TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reproducibility of the FFR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: World Health Organization Disability Assessment Schedule (WHODAS 2.0) Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Activities of Daily Living in Hoarding Scale Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life in Neurological Disorders (Neuro-QoL) Positive Affect and Well-Being Short form Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of hospital-acquired pressure injury
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in modified Rankin Scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants with One or More Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with One or More non-serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: strength of the biceps and triceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum oxygen uptake capacity (Vo2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standing long jump test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Health Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Muscle Activation Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of heart rate variability/ Autonomic nervous system evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mtb load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Coronal knee laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sagittal knee laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intra operative remifentanil administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in cardiometabolic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in endocrine measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fβ-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Attention - Dwell Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Attention - Time to First Fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Attention - Number of Fixations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNS BP response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of fentanyl and propofol during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of total acne lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Qualitative insights from interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of P. vivax patients treated according to G6PD enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-8 (IL-8) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Molecular profile of vascular habitat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell types and cell density description
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological description including tissues and necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum thromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Rating (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory - Short Form (BPI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Subjective Peripheral Neuropathy Screen Questionnaire (SPNSQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Orebro Musculoskeletal Pain Screening Questionnaire (OMSPQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Linear deviation of anatomical landmarks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenal insufficiency events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in innate immune signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) of TPN-101
Endpoint domain: Adverse events/effects
Primary endpoint: Acute technical success per the DISRUPT PAD definition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of transfemoral delivery of a TAVR system post IVL within 30 days of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intrinsic positive end expiratory pressure (PEEPi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total duration of combined spinal-epidural procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Migraine days per 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Congenital CMV infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Glucose and lipid concentrations in circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: biomarker validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest Medicine Ball Throw
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White Blood Cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abdominal muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transverse abdominis (TrA) muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in dentin hypersensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported capability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Transition time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of awakenings during the night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Average lesion fluorescence loss (∆F%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum lesion fluorescence loss (∆F-max%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liberation from invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of neoadjuvant BAY 43-9006 (sorafenib) and concurrent BAY 43-9006 with radiation
Endpoint domain: Adverse events/effects
Primary endpoint: Clavien-Madadi classification grading
Endpoint domain: Adverse events/effects
Primary endpoint: Awareness Scale Related To Physiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC for syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of fenofibrate
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity in the masticatory musculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications in the administration of botulinum toxin
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive status (impaired vs non impaired)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes from baseline in cognitive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: future cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety level measured by STAI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Friedreich Ataxia Rating Scale - Neurological Examination Part E (upright stability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration at the effect-site propofol associated with deep anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Complete COVID-19 Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Aggregate Executive Functioning Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Aggregate Memory Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Aggregate Language Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hospital Readmission Rate Within 30 Days of Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 90 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycosylated Hemoglobin (HbA1c) - Change From Baseline to 180 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acquisition of CVC procedural skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth vitality (positive response to cold test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of positive RT-PCR at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from Baseline Vocal Responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free from clinically-driven target lesion reintervention
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Stoma-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Completion of AD documentation at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline in Completion of AD documentation at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline in Completion of AD documentation at 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in daily Worst Itching Intensity Numerical Rating Scale (WI-NRS) scores from baseline during the administration period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of subjects whose daily WI-NRS scores improve by ≥ 3 points and ≥ 4 points compared with baseline during the administration period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in quality of life (evaluated by Skindex-16 scale) from baseline during the administration period
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the NNC0194-0499 serum concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Active Motion (TAM) score for target finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in NCS parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulated uncontrolled alcohol use days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum consecutive alcohol abstinent days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of any local and systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with presence of local skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Target Lobar Volume Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients reaching MEWS score ≥ 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major adverse cardiovascular events (MACE) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of clinically relevant bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Validity and sensitivity of OCT angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ventilation-perfusion matching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight bearing on the hemiplegic side
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: clinical response following completion of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in positive psychosis-like symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical daily practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: success rates of eradication treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Speech understanding in the presence of masking sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrically evoked compound action potentials (ECAPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biophysical profile (BPP) for fetal well being
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of population completing at least one KAP session
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: peak growth hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Masticatory and swallowing profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on oral health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual Symptom Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Reporting Any Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Adverse Events (AEs)/SAEs Leading to Study Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Any Unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of the visualFields easy App
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RBC to Membrane Ratio Pre and Post Transfusion or Apheresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in RBC Chemical Shift After Oxygen Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in RBC Oscillation Amplitude Post Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Antibiotic Prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post operative morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Dose Limiting Toxicities From Revumenib
Endpoint domain: Adverse events/effects
Primary endpoint: Squared coefficient of variation of the tidal volumetric strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ACPA-expressing B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Offloading adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients achieving HbS objectives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visual analogue scale (VAS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Percentage of Patients With an Adverse Event (AE) (Moderate or Severe)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in State-based anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants completing IV sotalol loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: radiotherapy-related anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Neutralising Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hand Foot Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum COX-2 Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Tumor Necrosis Factor Alpha Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of enrollment in clinical research
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite of cardiovascular death, stroke, and unplanned cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Unplanned cardiovascular hospitalization for heart failure or acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Binge Eating Frequency
Endpoint domain: Life impact
Endpoint subdomain: Eating behavior
Primary endpoint: Change in plasma [NO2-]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of airleak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale for pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Time from stroke onset to endovascular therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Accessing peer support
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of obtaining paired biopsy samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Collection of matched blood samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with failure of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Change in well-being (psychological flourishing)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fasted glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasted insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemia 2 hours following an oral glucose challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: two-minute walk test (2MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants relapsing after withdrawal of SOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants responding during the SAR445088 treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reported with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Open-Ended Achievement Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adult Motivation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distance Education Attitude Scale in Lifelong Learning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive Flexibility Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change at nasal polyp size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidural venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidural venous flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence Rate after Nd:YAG Laser treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of cure of the patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes